The only approved gene therapy for RP today targets a single gene RPE65, which accounts for just 1% to 2% of the total RP patient population. We believe OCU400 has significantly wider commercial ...
On February 27, Chad Larson, senior portfolio manager at MLD Wealth of CG Wealth Management, joined BNN Bloomberg to discuss ...
Enables ANSI-based Test Infrastructure to Seamlessly Accommodate Global IEC Meters Utilities across Southeast Asia, ...
Physicists confirmed the full two-dimensional six-state clock model in atomically thin nickel phosphorus trisulfide, ...
The first of four phases of homes in Toll Brothers’ Havenwood residential development was given the green light by Flower ...
The May 29, 2026 PDUFA targets pediatric approval of Afrezza for type 1 or type 2 diabetes, leveraging INHALE-1 outcomes versus rapid-acting analogs plus basal insulin. INHALE-1 was open-label and ...
Induction Yervoy (ipilimumab) plus Opdivo (nivolumab) followed by consolidative chemoradiotherapy demonstrated bladder ...
A large international clinical trial has unveiled a promising new option for people living with highly treatment-resistant HIV.
The 2026 GU ASCO annual meeting featured a testicular cancer session and a presentation by Dr. Jennifer King discussing a ...
After a median follow-up of 13.3 months (95% CI, 9.04-18.69), the median duration of response was 18.1 months, progression ...
March, affecting 7.3 million properties. Around one million owners will see major reductions, while others face higher charges depending on acquisitions and E9 declarations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results